Dr. Peguero received his MD from Ponce School of Medicine, Puerto Rico. He completed a neurology residency at the University of South Florida, Morsani College of Medicine. After completing his residency, Dr. Peguero completed a fellowship in epilepsy and EEG at Vanderbilt University School of Medicine. After his fellowship, Dr. Peguero was employed at The Watson Clinic, Department of Neurology, Lakeland, Florida, where he also served as Chief of Service of Neurology at Lakeland Regional Medical Center. Dr. Peguero was an Assistant Professor at Ponce School of Medicine, and most recently, he has worked in private practice. Dr. Peguero’s clinical interest is in General Neurology, Epilepsy and Clinical Neurophysiology. He will help expand our diagnostic and therapeutic strategies in Onco-Neurology using advanced electrophysiologic techniques in EMG and EEG. This capability is especially important in the Neurologic complications of novel therapies such as check point inhibitors and CAR-T therapies.
Education & Training
- Neurology - Clinical Neurophysiology
- Vanderbilt University School of Medicine - Epilepsy and EEG
- Damas Hospital - Internal Medicine
- University of South Florida - Neurology
- Ponce School of Medicine - MD
- Liu JKC, Kang R, Bilenkin A, Prorok R, Whiting J, Patel KB, Beer-Furlan A, Naso C, Rogers A, Castro XB, Peguero E, Mokhtari S, Tran N, Etame A, Pina Y, Spiess PE, Forsyth P, Vogelbaum MA. Patient satisfaction and cost savings analysis of the telemedicine program within a neuro-oncology department. J Neurooncol. 2022 Nov.160(2):517-525. Pubmedid: 36367630. Pmcid: PMC9651094.
- Lynes J, Rubino S, Rogers A, Gaballa S, Liu HD, Arrington JA, Peguero E, Liu JKC. Spontaneous Spinal Subdural Hematoma Secondary to Hemophilia A and Zanubrutinib. J Neurol Surg Rep. 2022 Jan.83(1):e19-e22. Pubmedid: 35273899. Pmcid: PMC8920709.
- Keerty D, Peguero E. Pembrolizumab-Induced Parsonage-Turner Syndrome. Neurol Clin Pract. 2021 Oct.11(5):e781-e783. Pubmedid: 34840909. Pmcid: PMC8610514.
- Keerty D, Kessler R, Koverzhenko V, Peguero E. Dyskinesia during concomitant usage of phenytoin and capecitabine. Postgrad Med J. 2021 Oct.97(1152):629. Pubmedid: 32769104.
- Akgul Babacan N, Peguero E, Forsyth P, Eroglu Z. BRAF Inhibitor Therapy-Related Encephalitis in a Patient with Metastatic Melanoma. Oncologist. 2021 Oct.26(10):e1887-e1889. Pubmedid: 34227206. Pmcid: PMC8488772.
- Vogelbaum MA, Kroll D, Etame A, Tran N, Liu J, Ford A, Sparr E, Kim Y, Forsyth P, Sahebjam S, Mokhtari S, Peguero E, Macaulay R. A Prospective Validation Study of the First 3D Digital Exoscope for Visualization of 5-ALA-Induced Fluorescence in High-Grade Gliomas. World Neurosurg. 2021 May.149:e498-e503. Pubmedid: 33561551.
- Tan E, Tran ND, Peguero E, Robinson T, Gaballa S. Lymphoplasmacytic lymphoma manifesting as a cervical spine mass with Parkinson-like symptoms treated with ibrutinib. Current Problems in Cancer: Case Reports. 2021 Mar.3.
- Verma N, Jaffer M, Pina Y, Peguero E, Mokhtari S. Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis. Cureus. 2021 Jul.13(7):e16337. Pubmedid: 34395120. Pmcid: PMC8357079.
- Fusco MJ, Piña Y, Macaulay RJ, Sahebjam S, Forsyth PA, Peguero E, Walko CM. Durable Progression-Free Survival With the Use of BRAF and MEK Inhibitors in Four Cases With BRAF V600E-Mutated Gliomas. Cancer Control. 2021 Jan.28. Pubmedid: 34620004. Pmcid: PMC8506147.
- Piña Y, Evernden BR, Khushalani N, Margolin K, Tawbi H, Tran ND, Macaulay R, Forsyth P, Peguero E. Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. SAGE Open Med Case Rep. 2021 Aug.9. Pubmedid: 34457306. Pmcid: PMC8392782.
- Sahebjam S, Forsyth PA, Tran ND, Arrington JA, Macaulay R, Etame AB, Walko CM, Boyle T, Peguero EN, Jaglal M, Mokhtari S, Enderling H, Raghunand N, Gatewood T, Long W, Dzierzeski JL, Evernden B, Robinson T, Wicklund MC, Kim S, Thompson ZJ, Chen DT, Chinnaiyan P, Yu HM. Hypofractionated stereotactic re-irradiation with pembrolizumab and bevacizumab in patients with recurrent high-grade gliomas: results from a phase I study. Neurooncol. 2021 Apr.23(4):677-686. Pubmedid: 33173935. Pmcid: PMC8041351.
- Piña Y, Fusco MJ, Macaulay RJ, Walko CM, Peguero E, Evernden BR, Smalley KS, Forsyth P. Using personalized medicine in gliomas: a genomic approach to diagnosis and overcoming treatment resistance in a case with pleomorphic xanthoastrocytoma. J Neurol. 2020 Mar.267(3):783-790. Pubmedid: 31748891. Pmcid: PMC7035305.
- Kasischke KA, Peguero EN, Sriaroon C, Moreo N, Ren Z, Mokin MV, Rose DZ. Immediate Transfer for Clot Extraction in a Young Woman With Leukemia and Asparaginase-Associated Acute Cerebral Vein Thrombosis. Neurohospitalist. 2020 Jan.10(1):58-63. Pubmedid: 31839868. Pmcid: PMC6900648.
- Jaffer M, Chung M, Sharda E, Ramsakal A, Peguero E, Verma N, Mokhtari S. Immunotherapy Induced Myasthenic-Like Syndrome in a Metastatic Melanoma Patient With Amyotrophic Lateral Sclerosis. Clin Med Insights Oncol. 2020 Dec.14. Pubmedid: 33447124. Pmcid: PMC7780164.
- Chung M, Jaffer M, Verma N, Mokhtari S, Ramsakal A, Peguero E. Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange. J Neurol. 2020 Apr.267(4):1023-1025. Pubmedid: 31832829.
- Maller B, Peguero E, Tanvetyanon T. Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. J Immunother. 2018 Nov.41(9):411-412. Pubmedid: 29742520.
- Peguero E, Abou-Khalil B, Fakhoury T, Mathews G. Self-injury and incontinence in psychogenic seizures. Epilepsia. 1995 Jun.36(6):586-591. Pubmedid: 7555972.
- Fakhoury T, Abou-Khalil B, Peguero E. Differentiating clinical features of right and left temporal lobe seizures. Epilepsia. 1994 Sep.35(5):1038-1044. Pubmedid: 7925149.
Patient CommentsOverall Satisfaction5
81 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.Learn more about our patient satisfaction survey
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.